-- First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax -- Oral NUZYRA Tablets Produced in the U.S. as a Result of the Company's Onshoring Initiative ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market Acquisition advances Paratek’s ...

I have been in the healthcare field for quite some time and luckily been pretty successful in determining when a small cap biotech has a product that is likely to progress in clinical trials or ...

Shares in Paratek were up almost a third in premarket trading this morning after Bloomberg said the company, gearing up to file a new antibiotic, is considering a sale. Last month, Paratek said a ...

The world needs new antibiotics, but regulators are having a difficult time convincing drugmakers to develop them — largely because of unresolved commercial restraints. Antibiotics, especially against ...

BOSTON, June 25, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted Paratek Pharmaceuticals orphan drug designation for Nuzyra to treat infections caused by ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Could a small clinical-stage emerging pharmaceuticals ...

Shares dive after the antibiotic drug developer announces the pricing details of a secondary common stock offering. Paratek announced on Wednesday that it wanted to raise $50 million through a common ...

The pharma company announced a debt offering that has Wall Street scrambling. The notes will mature on May 1, 2024 -- sufficiently far in the future -- and are redeemable for approximately 63 shares ...

Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to perform badly. Zooming in on an example, the Paratek Pharmaceuticals, Inc.

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 ...